Field of expertise
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:
Genetic Toxicology
We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.
Reproductive Toxicology
By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.
Mechanistic Toxicology
All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).
Toxys in 90 seconds
This video gives you a quick insight into what Toxys could do for you.
Happy Customers
We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:
"The differentiation between aneugens and clastogens is important in the hazard assessment of our pharmaceutical compounds. ToxTracker ACE conveniently combines the relevant endpoints to be able to do this"
“As a modern safety laboratory requiring mechanistic insights into mammalian toxicology, we adopted ToxTracker and installed the assay in-house. The expertise, training and support provided by Toxys for the technology transfer were excellent resulting in a seamless set-up of the assay in our facilities. In addition, we have had terrific reactivity from Giel and his team with our questions.”
"The ToxTracker assay is an excellent tool to evaluate the genotoxic potential of compounds, generating great additional value by dissecting the underlying genotoxic mechanisms, and thereby better assess the relevance of the genotoxic response in a fast and cost-efficient manner.”
“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”
"Orion has worked successfully with Toxys on a couple of occasions. We are happy with the open communication which makes planning the experiments and interpreting the results easy and straightforward. The assay is excellent follow-up for our in-house micronucleus test to reveal the mode-of-action and hence validate or in-validate the borderline positive/negative dilemma."
“A succesful genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”
"Mechanism-based screening assays like the ToxTracker can make a valuable contribution to the routine safety compliance screening of our products"
“The expertise at Toxys is clear when you discuss results. The proactive team works hard to generate results within the timelines"
Toxys newsletter September 2018
Here you can view our newsletter from September 2018 [campaign id="65e7479241"]...
New Animated ToxTracker Video
ToxTracker is a stem cell-based reporter assay for detection of genotoxicity and other cancer-related chemical properties of compounds. See below to play our new video to gain a detailed understanding of the various steps of the ToxTracker protocol and how the assay is performed in our...
Greatly improved metabolising system for ToxTracker
5 July 2018 - ToxTracker is an in vitro assay that provides detailed insight into the mode-of-action of genotoxic compounds. The assay is generally performed in the absence and presence of a metabolising system. Metabolic activation of compounds is included following the industry standard by...
Toxys newsletter May 2018
Here you can view our newsletter from May 2018 [campaign id="28b39f8a06"]...
Collaboration with Health Canada and University of Swansea to implement quantitative analysis of ToxTracker results for human risk assessment
Toxys has started a collaboration with Health Canada and the University of Swansea to implement the Quantitative Analysis tool PROAST for ToxTracker results. There is growing interest in quantitative analysis of in vitro genetic toxicity dose‐response data, and use of point‐of‐departure (PoD) metrics such as the...
ToxTracker applied for testing Cobalt nanoparticles
In collaboration with scientists at the Karolinska institute and KTH in Sweden, we recently published a paper about application of ToxTracker for genotoxicity testing of Cobalt nanoparticles. There is a growing demand for fast and reliable assays to identify nanoparticle-induced toxicity and underlying mechanisms. In the...
Toxys at SOT 2018 recap
Toxys had a busy program at the SOT 2018, next to the poster presentations and presentation at the Charles River sponsored session we organised our first ToxTracker workshop. First ToxTracker workshop Approximately 65 people have joined our first ToxTracker workshop. The workshop was started with a presentation...
ToxTracker and its application for read-across
The chemical industry and the REACH deadline REACH is the European legislation for Registration, Evaluation and Authorisation of CHemicals. It requires that each manufacturer or importer of chemicals in the European Union handling chemicals in quantities of 1 metric ton or more per year, to demonstrate...
Toxys newsletter January 2018
Here you can view our newsletter from January 2018 [campaign id="5376962ead"]...
First official ToxTracker workshop during SOT 2018
You are cordially invited to join the first official ToxTracker workshop during the SOT 2018 meeting in San Antonio. The workshop provides a unique opportunity to learn more about the ToxTracker reporter assay for cancer hazard assessment. We will update you on the latest developments...
